Lack of Primary Mutations Associated With Integrase Inhibitors Among HIV-1 Subtypes B, C, and F Circulating in Brazil

• DOI: 10.1097/qai.0b013e31819df3b3
• Publication Date: 2009-05-21T12:33:55Z
• Authors: Caroline Bittenco...; Monick Lindenmeye...; Saada Lima Cheque...; Roberta dos Santo...; Sylvia Lopes Maia...; José Carlos Couto...; Mariza Gonçalves ...
• Keywords: Elvitegravir; Raltegravir; Integrase inhibitor; Resistance mutation

Background: Antiretroviral drugs targeting integrase (IN) have recently been approved for use in combined and salvage therapeutic interventions. Objective: To evaluate the presence of natural polymorphisms resistance mutations associated with IN inhibitors among HIV-1 subtypes B, C, F samples obtained from drug-naive individuals patients failing highly active antiretroviral therapy Brazil. Methods: Proviral DNA was blood 105 HIV-1-positive infected by or plasma viral RNA 30 subtype B-infected therapy. The region amplified nested polymerase chain reaction automatically sequenced determination. Translated amino acid sequences were inspected resistance. Results: Eleven described as conferring vitro to strand transfer detected Brazilian samples. V72I V201I considered polymorphisms. Major elvitegravir raltegravir vivo (Q148K/H/R, N155H) not detected. Conclusions: Although some naturally occurring observed, absence major current provides a good rationale introduction these These results highlight importance continuous surveillance genetic diversity.